{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:33:10Z","timestamp":1777919590881,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T00:00:00Z","timestamp":1206662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T00:00:00Z","timestamp":1206662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"abstract":"<jats:p>Corticotropin-releasing factor injected intracerebroventricularly in a dose of 1 \u00b5g produced a prolonged locomotor activation (3 h) in rats previously habituated to the test cage environment. This activation was reversed by \u03b1-flupenthixol (intraperitoneally), a dopamine receptor antagonist, only at cataleptic doses and not at all by naloxone (subcutaneously) in doses of 0.02\u20135.0 mg\/kg. The effective dose 50% (ED&lt;sub&gt;50&lt;\/sub&gt;) for the \u03b1-flupenthixol reversal of locomotor activity induced by corticotropin-releasing factor was 0.13 mg\/kg; similar to the 0.14 mg\/kg ED&lt;sub&gt;50&lt;\/sub&gt; needed to reverse the locomotor activation produced by caffeine (10 mg\/kg s.c). The ED&lt;sub&gt;50&lt;\/sub&gt; necessary to reverse amphetamine (0.75 mg\/kg s.c.) locomotion with this drug was 0.07 mg\/kg. The results suggest that the corticotropin-releasing factor acts independently of direct activation of the dopamine or opioid peptide systems.<\/jats:p>","DOI":"10.1159\/000124021","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T16:47:51Z","timestamp":1206722871000},"page":"459-464","source":"Crossref","is-referenced-by-count":66,"title":["Effects of Alpha-Flupenthixol and Naloxone on CRF-Induced Locomotor Activation"],"prefix":"10.1159","author":[{"given":"George F.","family":"Koob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Swerdlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Seeligson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryruth","family":"Eaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Rivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wylie","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,3,28]]},"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/124021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000124021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:06:30Z","timestamp":1777662390000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000124021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000124021","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,28]]}}}